Response to a Letter Received Entitled: “‘Brief Report: Canadian Cancer Trials Group IND.227’: Unpacking the Clinical Potential of Single-Agent Pembrolizumab in Advanced Malignant Pleural Mesothelioma”
- Resource Type
- Correspondence
- Source
- In
Journal of Thoracic Oncology June 2023 18(6):e68-e69 - Subject
- Language
- ISSN
- 1556-0864